Heparan Sulfate Inhibits Hematopoietic Stem and Progenitor Cell Migration and Engraftment in Mucopolysaccharidosis I* 

Received for publication, July 30, 2014, and in revised form, October 22, 2014 Published, JBC Papers in Press, October 30, 2014, DOI 10.1074/jbc.M114.599944

H. Angharad Watson †, Rebecca J. Holley ‡, Kia J. Langford-Smith †, Fiona L. Wilkinson †, Toin H. van Kuppevelt ‡, Robert F. Wynn ‡, J. Edmond Wraith *, Catherine L. R. Merry †, and Brian W. Bigger †

From the Stem Cell & Neurotherapeutics Group, Faculty of Medical and Human Sciences, University of Manchester, Manchester M13 9PT, United Kingdom, Stem Cell Glycobiology Group, Faculty of Physical and Engineering Sciences, University of Manchester, Manchester M13 9PL, United Kingdom, Matrix Biochemistry Group, Department of Biochemistry, Radboud University Nijmegen Medical Center, 6500 HB Nijmegen, The Netherlands, Bone Marrow Transplantation Unit, Royal Manchester Children’s Hospital, Manchester M13 9WL, United Kingdom, and **Biochemical Genetics Unit, St. Mary’s Hospital, Manchester M13 9WL, United Kingdom.

Background: Hematopoietic stem cell transplantation in mucopolysaccharidosis I (MPSI) patients often results in graft failure.

Results: In mice with MPSI we linked reduced hematopoietic engraftment post-transplant to accumulated overly-sulfated extracellular heparan sulfate.

Conclusion: Excess extracellular heparan sulfate alters cytokine gradient formation, restricting stem cell migration.

Significance: This provides a mechanistic insight into the observed engraftment difficulties seen in patients.

Mucopolysaccharidosis I Hurler (MPSI-H) is a pediatric lysosomal storage disease caused by genetic deficiencies in IDUA, coding for α-L-iduronidase. Idua−/− mice share similar clinical pathology with patients, including the accumulation of the undegraded glycosaminoglycans (GAGs) heparan sulfate (HS) and dermatan sulfate (DS), progressive neurodegeneration, and dysostosis multiplex. Hematopoietic stem cell transplantation (HSCT) is the most effective treatment for Hurler patients, but reduced intensity conditioning is a risk factor in transplantation, suggesting an underlying defect in hematopoietic cell engraftment. HS is a co-receptor in the CXCL12/CXCR4 axis of hematopoietic stem and progenitor cell (HSPC) migration to the bone marrow (BM), but the effect of HS alterations on HSPC migration, or the functional role of HS in MPSI-H are unknown. We demonstrate defective WT HSCT engraftment and migration in Idua−/− recipient BM, particularly under reduced intensity conditioning. Both intracellular and extracellular Idua−/− BM HS was significantly increased and abnormally sulfated. Soluble heparinase-sensitive GAGs from Idua−/− BM and specifically 2-O-sulfated HS, elevated in Idua−/− BM, both inhibited CXCL12-mediated WT HSPC transwell migration, while DS had no effect. Thus we have shown that excess overly sulfated extracellular HS binds, and sequesters CXCL12, limiting hematopoietic migration and providing a potential mechanism for the limited scope of HSCT in Hurler disease.

Mucopolysaccharidosis type I (MPSI) is an inherited metabolic disease caused by a deficiency of α-L-iduronidase (IDUA), which leads to accumulation of heparan sulfate (HS) and dermatan sulfate (DS). Hurler disease (MPSI-H) is the most severe form, presenting in infancy with symptoms of skeletal dysplasia, abnormal facies, organomegaly, cardiac and respiratory defects, severe neurological degeneration, and death (1). Attenuated forms of the disease have much less significant neurological involvement and improved lifespan.

There are two current clinical treatment modalities for MPSI. Pharmacological enzyme replacement therapy (ERT), which relies on mannose-6-phosphate mediated uptake and cross-correction of affected cells, has limited effect on bone and neurological manifestations, as the enzyme fails to cross the blood brain barrier. Thus, ERT is only licensed for use in attenuated forms of MPSI (2, 3). Hematopoietic stem cell transplantation (HSCT) is an attractive alternative therapy, relying on the ability of donor derived monocytes to traffic and engraft in the brain as microglial cells (4), releasing enzyme here for cross correction. However, while successful transplants have resulted in significantly improved patient outcomes in MPSI-H, with extended life and improved neurological function, successful stable donor chimerism is difficult to achieve, with 44% of patients requiring a second or third transplant (5, 6). Risk factors identified in bone marrow (BM) and umbilical cord blood transplantation include reduced intensity conditioning regimens and age of treatment, with earlier treatment resulting in improved clinical outcomes. Recently, the introduction of fully myeloablative busulfan/cyclophosphamide conditioning (5–7), has significantly improved transplant success rates to over 90%.

* This work was supported in part by the UK Mucopolysaccharide Disease Society and by grants from the Ollie G Ball, the Lady Shauna Gosling Trust, and the National MPS Society (to H. A. W., F. L. W., and B. W. B.). This work was also supported by a grant from the Canadian MPS Society (to K. J. L.-S.), the Manchester Biomedical Research Center and the Manchester Academic Health Sciences Centre (to J. E. W. and B. W. B.), and by the Strategic Award (G9092170) from the Medical Research Council (UK) and British Heart Foundation, The Human Frontiers Science Program and the Engineering and Physical Sciences Research Council (to R. H. and C. L. R. M.).

† To whom correspondence should be addressed: Stem Cell & Neurotherapies, Faculty of Medical and Human Sciences, University of Manchester, Manchester, M13 9PT UK. Tel.: +44-161-3060516; E-mail: Brian.bigger@manchester.ac.uk.

The abbreviations used are: MPSI, mucopolysaccharidosis type I; MPSI-H, Hurler disease; GAG, glycosaminoglycans; HS, heparan sulfate; DS, dermatan sulfate; HSCT, hematopoietic stem cell transplantation; HSPC, hematopoietic stem and progenitor cell; BM, bone marrow; Idua; α-L-iduronidase; ERT, enzyme replacement therapy; HSPG, HS proteoglycan; GlcNAc, N-acetyl glucosamine; GlcA, glucuronic acid; IdoA, iduronic acid; AMAC, 2-aminoacridone; CFU, colony-forming units.
in some centers, but this requirement suggests an underlying engraftment defect in MPSI patients in one or all of hematopoietic stem cell maintenance, homing, or engraftment.

HS, which is stored to pathological excess in MPSI-H (8–10), is involved in all aspects of these processes, including signaling involving CXCL12 (11, 12), as well as the presentation of chemokines to ligands in haptotactic gradients (13, 14). HS is synthesized covalently linked to a core protein to form an HS proteoglycan (HSPG), which are found at the cell-matrix interface. HS is a long chain non-branching sulfated glycosaminoglycan (GAG), consisting of repeating disaccharide subunits of N-acetyl glucosamine (GlcNAc) and glucuronic acid (GlcA). The chain is modified in the Golgi apparatus during synthesis by the epimerization of a subset of GlcA residues to iduronic acid (IdoA) and the transfer of sulfates to the N-, 2-O-, 3-O-, and 6-O-positions, selectively altering regions of the chain to patches of modification, known as sulfated (S-) domains, separated by regions with little modification. Ultimately it is these modifications which determine the ability of the chain to bind different protein factors (15). Heparin is structurally similar to HS but lacks a domain structure, being very heavily modified along the entire chain.

CXCL12 via its cognate receptor CXCR4, is the primary mediator of hematopoietic stem and progenitor cell (HSPC) homing to the BM following transplantation (16). It is constitutively expressed by the BM, and expression is up-regulated following DNA damage and hypoxia, which both result from myeloablative transplant conditioning (17, 18). CXCL12 is presented to incoming cells via HS on the apical surface of endothelial cells, and cannot function in vivo without its HS binding site (19), which is structurally unique among cytokines, and exhibits a binding preference for regions containing 2-O-sulfation (20).

Here, we demonstrate that engraftment difficulties seen in the clinic are recapitulated in a mouse model of MPSI-H, and that the decrease in engraftment can be linked to a decrease in homing of transplanted cells to the BM. The BM of these mice contains significant amounts of stored HS, but rather than the HS being sequestered within the lysosomes, it is instead overwhelmingly located in the extracellular matrix of the BM stroma, making it available for protein interactions. The accumulated HS is rich in the 2-O-sulfation modification preferred by CXCL12, while levels of CXCL12 are increased in the BM niche of affected mice. However, we demonstrate that rather than improving migration of HSPCs to the BM, the excess, highly sulfated HS is inhibiting migration toward CXCL12, resulting in homing and engraftment defects.

**Experimental Procedures**

**Mice**—Donor and recipient mice differentially expressed CD45 epitopes using crosses of B6.SJ-Lptpc/oPepc/oBoyJ (CD45.1) (Jackson Laboratories), C57BL6 (CD45.2) and heterozygote CD45.1xCD45.2 F1 mice, generated on WT or B6.129-IduamCIkJ (Iduam−/−) backgrounds (21). Mice were maintained according to UK Home Office regulations with food and water *ad libitum*.

**BM Transplantation**—6–9-week-old recipient mice were maintained on acidified water and irradiated feed for 7 days prior to transplant. Mice were either lethally irradiated in two 5 Gy doses 4 h apart (full intensity), or myeloablative using 125 (full intensity) or 25 mg/kg (reduced intensity) Busulfan (Busilvex, Pierre Fabre), via intraperitoneal injection as previously described (22–24). Fresh whole bone marrow or lineage-depleted cells were delivered via tail vein 1 h post-irradiation or 24 h post-Busulfan. Mice were sacrificed at 18 h (whole BM migration), 36 h (lineage depleted migration) 6 weeks (short term engraftment), or 20 weeks (long term engraftment) and BM, peripheral blood, spleen recovered and analyzed by flow cytometry to measure donor chimerism as previously described (22).

**Leukocyte Preparation**—BM or blood was collected, washed and erythrocytes lysed using ammonium chloride lysis. Extracted leukocytes were re-suspended in PBS/2% FCS for lineage negative separation (Stem Cell Technologies) or Sca1+ separation (Miltenyi) using double LS column selection, according to manufacturer’s recommendations. Enriched cell populations were resuspended in X-Vivo10 for migration and whole BM stored in at > −80 °C in 10% DMSO/40% FCS. For quantification of total BM, cells from only one femur and one plexus negative separation (Stem Cell Technologies) or Sca1+ separation (Miltenyi) using double LS column selection, according to manufacturer’s recommendations. Enriched cell populations were resuspended in X-Vivo10 for migration and whole BM stored in at > −80 °C in 10% DMSO/40% FCS. For quantification of total BM, cells from only one femur and one tibia per mouse were extracted and counted. Colony-forming assays were performed in triplicate as described previously with 2 × 10⁴ cells/ml for BM and 1 × 10⁵ cells/ml for peripheral blood and counted 12 days later (22–24).

**CXCL12 Quantification**—Quantification of CXCL12 was performed using a quantitative immunosorbent assay kit (R&D Systems) on the soluble fraction of BM extracted from a single femur and tibia in a total volume of 200 μl of PBS, and centrifuged at 300 × g to remove cells.

**Bone Marrow Stromal Cell Culture**—BM cells were isolated and lysed as described, but with additional mechanical abrasion of the interior of the bones using a 29 G needle, to extract MSCs residing at the endostium (25). Cells were cultured in α-MEM (Lonza) with 12.5% horse serum, 12.5% FCS, 0.1 μg/mL hydrocortisone, 2 mM L-glutamine, and 50 units of penicillin/50 μg of streptomycin. Passage 5–15 cells were characterized by flow cytometry with the following expression profile: CD45+*, CD11b−, Sca1+, CD44−, CD105−.

**In Vitro Migration Assays**—Solutions of HS, DS, or selectively desulfated heparins (Iduron), or 0.1% gelatin (Sigma) was used to coat the insert of a transwell plate (Costar 6.5 mm well, 6.5 μm pore inserts). Prior to migration, excess coating solution was aspirated, and inserts were washed once in PBS. For migration toward CXCL12, migration medium (X-Vivo 10) (R&D) was added to the lower well (n = 8). For all assays, cells were counted in triplicate and resuspended at 1 × 10⁵ cells/ml for whole, unsorted BM, or 1 × 10⁴ for HSPC enriched populations, in migration medium (X-Vivo 10, Lonza/5% FCS). Fractions were collected as above, and processed as described (22–24). Fresh whole bone marrow or lineage-depleted cells were delivered via tail vein 1 h post-irradiation or 24 h post-Busulfan. Mice were sacrificed at 18 h (whole BM migration), 36 h (lineage depleted migration) 6 weeks (short term engraftment), or 20 weeks (long term engraftment) and BM, peripheral blood, spleen recovered and analyzed by flow cytometry to measure donor chimerism as previously described (22).

**BM Transplantation**—6–9-week-old recipient mice were maintained on acidified water and irradiated feed for 7 days prior to transplant. Mice were either lethally irradiated in two 5 Gy doses 4 h apart (full intensity), or myeloablative using 125 (full intensity) or 25 mg/kg (reduced intensity) Busulfan (Busilvex, Pierre Fabre), via intraperitoneal injection as previously described (22–24). Fresh whole bone marrow or lineage-depleted cells were delivered via tail vein 1 h post-irradiation or 24 h post-Busulfan. Mice were sacrificed at 18 h (whole BM migration), 36 h (lineage depleted migration) 6 weeks (short term engraftment), or 20 weeks (long term engraftment) and BM, peripheral blood, spleen recovered and analyzed by flow cytometry to measure donor chimerism as previously described (22).

**Accumulated HS Inhibits HSPC Engraftment in MPSI**

Fresh whole bone marrow or lineage-depleted cells were delivered via tail vein 1 h post-irradiation or 24 h post-Busulfan. Mice were sacrificed at 18 h (whole BM migration), 36 h (lineage depleted migration) 6 weeks (short term engraftment), or 20 weeks (long term engraftment) and BM, peripheral blood, spleen recovered and analyzed by flow cytometry to measure donor chimerism as previously described (22).

**Leukocyte Preparation**—BM or blood was collected, washed and erythrocytes lysed using ammonium chloride lysis. Extracted leukocytes were re-suspended in PBS/2% FCS for lineage negative separation (Stem Cell Technologies) or Sca1+ separation (Miltenyi) using double LS column selection, according to manufacturer’s recommendations. Enriched cell populations were resuspended in X-Vivo10 for migration and whole BM stored in at > −80 °C in 10% DMSO/40% FCS. For quantification of total BM, cells from only one femur and one tibia per mouse were extracted and counted. Colony-forming assays were performed in triplicate as described previously with 2 × 10⁴ cells/ml for BM and 1 × 10⁵ cells/ml for peripheral blood and counted 12 days later (22–24).

**CXCL12 Quantification**—Quantification of CXCL12 was performed using a quantitative immunosorbent assay kit (R&D Systems) on the soluble fraction of BM extracted from a single femur and tibia in a total volume of 200 μl of PBS, and centrifuged at 300 × g to remove cells.

**Bone Marrow Stromal Cell Culture**—BM cells were isolated and lysed as described, but with additional mechanical abrasion of the interior of the bones using a 29 G needle, to extract MSCs residing at the endostium (25). Cells were cultured in α-MEM (Lonza) with 12.5% horse serum, 12.5% FCS, 0.1 μg/mL hydrocortisone, 2 mM L-glutamine, and 50 units of penicillin/50 μg of streptomycin. Passage 5–15 cells were characterized by flow cytometry with the following expression profile: CD45+*, CD11b−, Sca1+, CD44−, CD105−.

**In Vitro Migration Assays**—Solutions of HS, DS, or selectively desulfated heparins (Iduron), or 0.1% gelatin (Sigma) was used to coat the insert of a transwell plate (Costar 6.5 mm well, 5 μm pore inserts). Prior to migration, excess coating solution was aspirated, and inserts were washed once in PBS. For migration toward CXCL12, migration medium (X-Vivo 10) (R&D) was added to the lower well (n = 8). For all assays, cells were counted in triplicate and resuspended at 1 × 10⁵ cells/ml for whole, unsorted BM, or 1 × 10⁴ for HSPC enriched populations, in migration medium (X-Vivo 10, Lonza/5% FCS). Cells in 100 μl migration medium were added at RADBOUD UNIVERSITEIT NIJMEGEN on March 6, 2017http://www.jbc.org/Downloaded from
**Accumulated HS Inhibits HSPC Engraftment in MPSI**

relevant starting volume of PBS. A portion of $Idua^{-/-}$ GAGs were digested with heparinas as described previously (10). 2 $\times$ 10^5 lineage depleted BM cells/well were migrated in the presence of 2% FCS/6.25% GAGs in X-VIVO 10 toward CXCL12 (200 ng/ml) for 8 h at 37 °C across gelatin-coated 5-μm pore transwell inserts. Migrated and un-migrated cells were counted by flow cytometry (BD FACS CANTO II) using CytoCount Control Beads (Brookhaven Instruments Ltd).

**Flow Cytometry**—All flow cytometry was carried out on a BD FACS CANTO II flow cytometer, using Facs Diva (BD), Flowjo (TreeStar) or Weasel (WEHI Institute) software for analysis. ToPro3 (Invitrogen) or 7AAD (BD Biosciences) were used as viability stains. For the identification of hematopoietic stem and progenitor populations, the following antibodies were used: Rat αMouse C-Kit FITC; Lineage Mixture (CD3e, CD11b, CD45R, TER-119, Ly6G, Ly6C) APC; Rat αMouse Sca-1 PE; Rat αMouse CD45 APC-Cy7 (all BD Biosciences). For the identification of mature hematopoietic lineages, the following antibodies were used: Rat αMouse CD11b PE-Cy7; Rat αMouse CD19; Rat αMouse CD3 PerCP-Cy5.5 (all BD Biosciences). For measurement of donor chimerism: Mouse αMouse CD45.1 PE Mouse αMouse CD45.2 (BD Biosciences). For the characterization ofMSCs: Rat αMouse C-Kit FITC; Rat αMouse CD11b PE-Cy7; Rat αMouse Sca-1 PE; Rat αMouse CD45 APC-Cy7; Rat αMouse CD44 PerCP Cy5.5; Rat αMouse Sca-1 PE-Cy7 (BD Biosciences), and Rat αMouse CD105 FITC (R&D Systems).

For the analysis of HS, the following phage display scFv antibodies were used: HS4C3, RB4EA12 and MPB49 as described previously (26, 27).

**Immunofluorescence**—WT and MPSI MSCs were cultured on Permanox chamber slides (Lab-Tek) and fixed with 4% paraformaldehyde, staining as described previously (27). Where required, slides were treated with 2 mL U heparinase I, II, and III in PBS for 1 h at room temperature prior to permeabilization. Antibodies used were LAMP2 (University of Iowa), 10E4 and, 3G10 (both Seikagaku), rat-Alexa546, mouse IgM-Alexa488, and mouse IgG-Alexa488 (all Invitrogen). Images were collected using a Nikon C1 confocal on an upright 90i microscope with a 60× oil immersion objective, with z-stacked images collected at 0.5-μm intervals. Images were processed in ImageJ (NIH/MacBiophotonics) and presented as z-projections at maximum intensity.

**GAG/CXCL12 ELISA**—BD Heparin Binding Plates (BD Biosciences) were used in all assays. HS, DS, and heparin (Iduron) were dissolved in PBS at concentrations of 0.05–12.8 μM based on approximate “average” disaccharide MWs. Plates were coated with GAG overnight at room temperature then washed with Wash Buffer (100 mM NaCl, 50 mM NaAc, 0.2% Tween20, pH 6.0), blocked with Wash Buffer +1% BSA (Sigma) for 90 min at 37 °C. Following incubation with 200 ng/ml CXCL12 in PBS for 90 min at 37 °C, wells were blocked with Wash Buffer/5% goat serum (Vector Labs) before adding 1:1000 polyclonal rabbit anti-human CXCL12 antibody (AbCam) for 1 h at room temperature. Wells were stained with biotinylated goat anti-rabbit IgG (Vector Labs,1:2000), amplified with Vectastain Elite ABC reagent (Vector Labs) and developed with OPD substrate (Sigma) as per manufacturer’s instructions. Absorbance at 490 nm was measured using a Synergy HT Microplate Reader (BioTek).

**2-Aminoacridone (AMAC) Labeling for High Performance Liquid Chromatography Disaccharide Analysis**—Leukocytes were extracted as described above. Supernatant from all wash and lysis steps was reserved for the extracellular niche fraction. The cell pellet was resuspended to form the cell fraction. Glycosaminoglycan chains were then purified, AMAC labeled and analyzed by RP-HPLC essentially as described previously (10). Because the efficiency of AMAC labeling varies according to specific disaccharides, the raw peaks were multiplied by the following correction factors determined by comparison to UV traces for individual disaccharides: UA2S-GlcNS6S, 1.25; UA-GlcNS(6S) 1.13; UA(2S)-GlcNS, 1.0; UA-GlcNS, 1.04; UA-GlcNAc(6S), 1.13; UA(2S)-GlcNAc, 0.97; UA-GlcNAc, 1.08. Quantification of the amount of HS contained within cell and matrix fractions was made by comparison of fluorescence with known quantities of HS.

**Statistical Analysis**—Comparisons of means was performed using either a two-tailed Student’s t test, or one-way or 2-way ANOVA using JMP software (SAS Institute Inc.) appropriate to the number of means and variables compared. Post-hoc analysis used Tukey’s multiple comparisons. p values of less than or equal to 0.05 were considered significant. Error bars refer to the standard error of mean.

**RESULTS**

**Idua−−** Mice Demonstrate a Defect in HSPC Engraftment and Bone Marrow Migration—To establish if an engraftment defect was present in MPSI and to mimic the treatment approach used in MPSI-H patients, we used HSCT in the Idua−− mouse model, which accumulates HS and DS and shares similar neuropathological features with MPSI patients (21, 28). Following full myeloablation of Idua−− or WT mice and transplantation with WT BM (23), full donor chimerism was achieved in all recipients at 6 weeks (Fig. 1A), although a small but statistically significant decrease in peripheral blood and spleen donor chimerism in Idua−− recipients was observed. We introduced limiting conditions for engraftment with reduced-intensity conditioning, resulting in a highly significant engraftment defect in Idua−− recipients at both high, or low cell doses (Fig. 1B).

Previous analysis of mesenchymal stromal cells (MSCs) derived from bone marrow of MPSI-H patients, suggested that they were not able to maintain the colony-forming properties of HSCs as well as normal MSCs (29). This implied that the BM niche may be detrimental to hematopoiesis in MPSI. However, our analysis of total leukocytes in the BM suggested normal hemostasis in MPSI mice (Fig. 2A), supported by analysis of phenotypic markers of mature and naive hematopoietic populations (Fig. 2, A and B) and colony forming ability in the BM (Fig. 2C), both of which indicated no abnormality in the maintenance of mature or naive hematopoietic lineages in Idua−− BM. Interestingly, we did observe reduced colony forming units (CFU) in the peripheral blood of Idua−− mice (Fig. 2D), suggesting retention of HSPCs in the Idua−− BM compartment.

Short-term analysis of the ability of WT donor BM to migrate to the myeloablated bone marrow of recipients, revealed a sig-
sific decrease in the number of WT donor cells reaching the BM compartment in Idua^{−/−} recipients (Fig. 3A), that became more pronounced when using a donor BM lineage negative fraction enriched for HSPC (Fig. 3B). Reduced HSPC migration might suggest a decrease in the production of the chemokine CXCL12, known to be responsible for HSPC migration and retention in the Idua^{−/−} BM. However, analysis of CXCL12 concentration in the BM niche revealed significantly increased concentrations in Idua^{−/−} BM both before and after myeloablation (Fig. 3, C and D). Therefore the observed homing and engraftment defects are not due to decreased CXCL12. On the contrary, elevated levels of CXCL12 in the Idua^{−/−} BM (Fig. 3, C and D) may be responsible for the decreased levels of circulating HSPC observed in (Fig. 2D), supporting the hypothesis of increased retention of HSPCs in the BM niche.

Idua^{−/−} Bone Marrow Contains Excess Intra- and Extracellular HS in Non-lysosomal Locations That Is Rich in Sulfate Modifications, Particularly 2-O-Sulfation—CXCL12 relies on GAGs to form haptotactic gradients, which are thought to guide CXCL12 mediated migration (12). In addition, CXCL12 contains a unique HS binding site (11), permitting dimerization and CXCR4 receptor binding. CXCL12 binding is furthermore dependent on the level and pattern of sulphation of HS (11, 20, 30, 31). Thus we reasoned that alterations in the level and sulfation patterning of HS could alter the ability of HSPCs to migrate to CXCL12 gradients. Previous studies have been conflicting regarding quantities of HS stored and the level of sulfation in MPSI (32–34), and although we have identified similar patterns of increased and abnormally sulfated HS in tissue and serum in both Idua^{−/−} mice and MPSI patients (10), the BM has not been examined, nor the relative levels of intra- and extracellular HS quantified.

Biochemical analysis of the composition of HS in cellular and extracellular BM fractions, using reverse-phase HPLC and AMAC labeling (35), indicated that there is a significant increase in all sulfated disaccharides in both BM fractions in Idua^{−/−} mice, with the greatest increase being in overall levels of 2-O-sulfate and N-sulfate modifications, and in particular, the HexA(2S)-GlcNS and HexA(2S)-GlcNS(6S) disaccharides (Fig. 4, A and 4B). Notably the proportion of disaccharides which are N-sulfated within Idua^{−/−} BM exceeds those which are N-acetylated. The most marked increase in HS accumulation was observed in the soluble extracellular BM fraction, not the cell fraction; a 33-fold increase in extracellular HS (average of 0.28 μg HS per WT BM compared with ~9.4 μg of HS in Idua^{−/−} was visible compared with a 2.4-fold increase (average of 0.31 μg of HS in WT BM versus ~0.73 μg in Idua^{−/−}) in the cell fraction (Fig. 4C). Interestingly, WT BM has similar amounts of HS in the cell and extracellular fractions. However most of the excess stored HS in Idua^{−/−} BM is in the extracel-
Accumulated HS Inhibits HSPC Engraftment in MPSI

lular BM niche, (~13-fold more than is stored in the cell fraction); the same location in which we found elevated levels of CXCL12 (Fig. 3, C and D). Analysis of CD45<sup>+</sup>, CD105<sup>+</sup>, CD44<sup>+</sup> primary BM derived MSCs with phage-display scFv antibodies directed against specific three-dimensional sulfated HS epitopes, supports the disaccharide analysis, with increased binding of HS4C3 and RB4EA12 (Fig. 4D), both of which have been shown to recognize highly sulfated epitopes in HS, enriched for 6-O- and N-sulfation (36–38).

The 10E4 epitope lies in N-sulfated regions of the HS chain, but is destroyed through the combined and complete action of bacterial heparinases. Immunofluorescent staining of HS in MSCs confirmed a significant increase in cellular and matrix HS (Fig. 5A). Furthermore there was a marked absence of HS co-localized with LAMP2 in the lysosomal compartment, in agreement with our previous findings (10). Controlled heparinase treatment of Idua<sup>−/−</sup> MSCs prior to permeabilization and staining, revealed non-lysosomal associated perinuclear 10E4 staining within the cell (Fig. 5B), co-localizing with the Golgi marker giantin. This staining was not strongly visible in WT cells (Fig. 5B). Therefore accumulated HS in BM MSCs is observed at the cell surface, in the ECM and in both lysosomal and non-lysosomal compartments. The 3G10 epitope is created by the action of heparinases, recognizing the unsaturated uronic acid stub remaining attached to proteoglycan cores (40). Thus it can provide information on the distribution of HS chains and therefore the proteoglycan cores within a tissue and potentially the number of HS chains (as only one 3G10 antibody can bind per chain). In WT cells, punctate 3G10 staining following heparinase digestion was seen across the surface of cells (Fig. 5C). However staining of Idua<sup>−/−</sup> cells revealed extensive cell surface and ECM staining, with much of the epitopes remaining in tight bundles spanning across cell junctions (Fig. 5D).

FIGURE 3. Homing to the Idua<sup>−/−</sup> BM is impaired despite increased niche CXCL12. A, flow cytometric quantification of percentage of CD45-positive WT donor BM cells or <i>B</i>, lineage-depleted donor WT HSPCs migrating to the BM of WT or Idua<sup>−/−</sup> recipients following lethal myeloablation and transplant with 2×10<sup>7</sup> donor cells (n = 5–6). C and D, CXCL12 concentration in BM soluble fraction of WT and Idua<sup>−/−</sup> mice, measured by quantitative ELISA (n = 5–15) in untreated mice (C) or 4 h after full myeloablation (D) (n = 5–6). Error bars represent ± S.E.

FIGURE 4. Elevated amounts of abnormally sulfated HS in the intra- and extracellular bone marrow niche of Idua<sup>−/−</sup> mice. Disaccharide analysis of HS in the cellular (A) and extracellular (B) fraction of whole BM from Idua<sup>−/−</sup> and WT mice was quantified by AMAC-tagged compositional analysis following complete digestion of the HS with combined heparinases. Inset: percentage contribution fractions for each sulfation position. C, total amount of HS in cellular and extracellular BM fractions. Amount of Idua<sup>−/−</sup> BM is expressed as μg HS per bone marrow calculated from AMAC fluorescent readings compared with readings from measured amounts of HS standards. Data are compiled from a minimum of 5 separate mice of each genotype, separately digested, and analyzed at least twice. D, flow cytometric analysis of WT or Idua<sup>−/−</sup> bone marrow-derived MSCs using HS-pattern specific antibodies. MPB49 is a non-HS binding control antibody. Data representative of eight independent experiments. Error bars represent ± S.E.
Accumulated HS Inhibits HSPC Engraftment in MPSI

HSPCs, compared with WT supernatant (Fig. 6A). To eliminate the possibility of protein interactions, including CXCL12 saturation, being responsible for the inhibition of migration, GAGs chains were purified from Idua−/− or WT BM, including a protease and boiling step to degrade/denature co-purified proteins. Purified Idua−/− GAGs resulted in a similar reduction in CXCL12 mediated migration of WT HSPC to CXCL12 (Fig. 6B). Critically this effect was eliminated by pre-treating the purified GAGs with HS-degrading heparinases prior to transwell migration, ruling out involvement of excess DS or chondroitin sulfate, and confirming a role for HS in decreased HSPC migration (Fig. 6B).

**Highly Sulfated HS and Heparin Bind CXCL12 in a Dose-dependent Manner**—A dose-dependent decrease in CXCL12-mediated HSPC migration was also obtained when increasing amounts of HS were immobilized on the transwell migration membrane (Fig. 6C). Thus, suggesting that both soluble and immobilized HS can block migration. To demonstrate that HS was binding CXCL12 in a sulfation and dose dependent manner, GAG was immobilized on the membrane, incubated with CXCL12, washed, and then a CXCL12 antibody was used to probe for CXCL12-GAG binding. Only high concentrations of HS (10 μm) were effectively able to capture CXCL12. Heparin, which is a fully sulfated analog of HS, bound CXCL12 at lower concentrations than HS (Fig. 6D), whereas DS was unable to bind. This is in keeping with previous work (20) showing that CXCL12 preferentially binds to the sulfated regions of HS (which in HS are normally interspersed by regions of low sulfation modification).

**2-O-Desulfation of Heparin Rescues CXCL12-mediated Hematopoietic Migration**—Finally, we coated transwell membranes with selectively desulfated heparin, to highlight the importance of different sulfate residues, and observed their effect on CXCL12-mediated migration of WT HSPC. HS, 6-O-desulfated and N-desulfated heparin reduced overall HSPC migration, mimicking the effect seen with Idua−/− BM GAG fractions; both 2-O-desulfated heparin and DS had no inhibitory effect (Fig. 6E). Thus these data strongly suggest that 2-O-sulfation is essential for CXCL12 binding and excess 2-O-sulfated HS in Idua−/− animals binds and functionally inhibits CXCL12-mediated HSPC migration, a modification which we found to be over-represented in Idua−/− BM.

**DISCUSSION**

The ability of most lysosomal enzymes to cross-correct neighboring cells via the mannose-6-phosphate pathway makes HSCT an attractive treatment option for lysosomal diseases. Despite this, HSCT is still only used for a handful of lysosomal diseases, including MPS-I-H. Reduced intensity conditioning could significantly improve the safety of HSCT in MPS-I-H, potentially broadening its scope to attenuated disease. In principle, stable mixed chimerism is all that should be required for cross-correction, however reduced intensity conditioning regimens are rarely successful, and the reasons for this are not well understood (5, 6). Previous studies have investigated the effect of HS/DS storage on developmental signaling pathways, however conclusions regarding the nature of the accumulated HS, and thus its effect on signaling pathways, have been contradic-

---

**FIGURE 5. HS is accumulated in non-lysosomal intracellular compartments including the Golgi.** A, confocal images of MSCs from WT or Idua−/− mice stained for the lysosomal marker Lamp2 (red) and HS (10E4, green). Nuclei were stained with DAPI. Scale bar = 50 μm. B, WT and Idua−/− MSCs were treated with heparinases prior to permeabilization and subsequently stained with Giantin and 10E4. Scale bar = 25 μm. C, WT and Idua−/− MSCs were treated with heparinases prior to permeabilization and subsequently stained with Lamp2 and 3G10. Scale bar = 50 μm.
Accumulated HS Inhibits HSPC Engraftment in MPSI

Using the Idua−/− mouse model of MPSI-H we demonstrated that there is a defect in both HSPC migration and engraftment in MPSI-H. However, interestingly the engraftment defect is only significant under limiting transplant conditions, while the migration defect is measurable even at saturating cell doses and full myeloablation. This suggests that the migration defect is constitutive but only contributes to graft failure under sub-optimal conditions for graft acceptance, where cell numbers are limiting, or where reduced intensity conditioning is used. The absence of an engraftment defect in non-limiting conditions, together with evidence that hematopoiesis and hemostasis in the Idua−/− mouse are indistinguishable from WT, suggests a BM niche that is supportive of engraftment.

In challenge to the current understanding of lysosomal storage diseases, we demonstrated a 13-fold excess of HS in extracellular locations in the Idua−/− BM niche, at least some of which is still bound to a protein core, presenting a system in which it is possible that multiple signaling pathways may be altered. Notably, the detection of non-reducing HS end structures in the plasma of patients with MPSI (42), suggests that HS is being partly degraded in the lysosome and released. The large excess of HS that we see in the ECM, existing most likely as a mixture of proteoglycan "bound" 3G10 positive cores and free 10E4 positive chains may be contributing to reduced mobility.
Accumulated HS Inhibits HSPC Engraftment in MPSI

Of HS in and out of cells. This results in accumulation in the ECM and consequential sequestration of cytokines and chemokines including CXCL12, thus altering critical signaling pathways.

CXCL12-mediated homing of HSPCs to the BM following transplantation relies on the formation of appropriate haptotactic gradients involving HS (Fig. 7). The requirement for HS in CXCL12-mediated migration is demonstrated in a study where mice expressed a mutant form of CXCL12 unable to bind HS. Increased circulating CXCL12 and reduced migration of CD34+ cells to sites of ischemic injury was observed due to an absence of haptotactic CXCL12 gradients (43). Furthermore, it has been shown that entry and egress of HSPCs to the bone marrow may be controlled through manipulations of HS. For instance, a number of studies (30, 31), have indicated that increases in circulating GAG mimetics lead to egress of CXCL12 from the BM niche into circulation, and a concomitant mobilization of circulating HSPCs. We have previously shown elevated HS in the circulation of the Iduna−/− mouse and MPSI patients (44, 45), which might be expected to behave in the same way as circulating GAG mimetics, increasing HSPC egress from the BM. However, within the Iduna−/− mouse, the significant increase in BM niche HS is conversely mitigating the effect of circulating HS, essentially trapping CXCL12 in the BM niche, and consequently decreasing circulating HSPCs. The CXCL12 gradients presented in Fig. 7 might suggest that migration would be normal in the Iduna−/− mouse (CXCL12 being at the highest concentration where HS is most localized, in the BM), and possibly even better than WT, given the higher concentration of CXCL12. However, our observations, together with previous studies on the affinity of CXCL12 for 2-O-sulfated HS, suggest that high-affinity binding of CXCL12 by heavily sulfated Iduna−/− HS is preventing CXCL12 from forming effective haptotactic gradients, resulting in sequestration of CXCL12 in the BM (Fig. 7B).

Although full intensity busulfan conditioning, does not increase the numbers of donor HSPC reaching the BM (46), it does provide a more permissive environment for engraftment of donor HSPC by eliminating a greater proportion of recipient BM, thus creating niche space. The defect in HSPC migration and excess of GAG in Iduna−/− BM strongly suggest that HSCT in HS storage diseases such as MPSI-H should use full intensity conditioning, and provide a mechanism by which this strategy is successful in improving MPSI patient engraftment outcomes (5, 7). Our data also suggest that strategies such as ERT, which reduce the amount of HS in and around cells prior to transplant, may improve donor chimerism outcomes by reducing HS-mediated homing inhibition in patients. MPSI-H patients are known to raise significant inhibitory antibody responses to ERT that are subsequently abolished by successful HSCT (39). Thus, abbreviated pre-transplant ERT regimens may be preferable to avoid inactivation of delivered enzyme prior to HSCT to maximize outcomes, and this warrants further investigation.

In conclusion, we show that highly 2-O-sulfated HS is present in excess in extracellular locations in the BM in MPSI-H, and in this context has an unexpected role in inhibiting HSPC migration into, and out of, the BM by sequestering CXCL12. Our data further define the functional role of HS in CXCL12-mediated HSPC migration and suggest a viable treatment approach for achieving successful outcomes with HSCT after reduced intensity conditioning in MPSI-H.

Acknowledgments—We gratefully acknowledge the help and assistance of the staff at the Manchester BSLI. The Bioimaging Facility microscopes used in this study were purchased with grants from BBSRC, Wellcome, and the University of Manchester Strategic Fund. Special thanks go to Robert Fernandez for help with the microscopy and image processing.

REFERENCES

1. Muenzer, J., Wraith, J. E., Clarke, L. A., and and the International Consensus Panel on the Management and Treatment of Mucopolysaccharidoses, I. (2009) Mucopolysaccharidosis I: Management and Treatment Guidelines. Pediatrics 123, 19–29

2. Wraith, J. E. (2005) The first 5 years of clinical experience with iduronate enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin. Pharmacother 6, 489–506

3. Wraith, J. E. (2006) Limitations of enzyme replacement therapy: current and future. J. Inherit. Metab. Dis. 29, 442–447

4. Wilkinson, F. L., Sergijenko, A., Langford-Smith, K. J., Malinowska, M., Wynn, R. F., and Bigger, B. W. (2013) Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation. Molecular Therapy 21, 868–876

5. Boelens, J. J., Rocho, V., Aldenhoven, M., Wynn, R., O’Meara, A., Michel, G., Jonec, I., Parikh, S., Prasad, V. K., Szabolcs, P., Escolar, M., Gluckman, E., Cavazzana-Calvo, M., Kurtzberg, J., Eurocord, I. e. W. P. o. E., and Duke, U. (2009) Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol. Blood Marrow Transplant 15, 618–625

6. Boelens, J. J., Wynn, R. F., O’Meara, A., Veys, P., Bertrand, Y., Souillet, G., Wraith, J. E., Fischer, A., Cavazzana-Calvo, M., Sykora, K. W., Sedlacek, P., Rovelli, A., Uiterwaal, C. S., and Wulfraat, N. (2007) Outcomes of hematopoietic stem cell transplantation for Hurler’s syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 40, 225–233
Accumulated HS Inhibits HSPC Engraftment in MPSI

7. Wynn, R. F., Wraith, J. E., Mercer, J., O’Meara, A., Tylee, K., Thornley, M., Church, H. J., and Bigger, B. W. (2009) Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J. Pediatr. 154, 609–611

8. de Ru, M. H., van der Tol, L., van Vliet, N., Bigger, B. W., Hollak, C. E., Ijsbrand, L., Kulk, W., van Lenthe, H., Saif, M. A., Wagmans, T., and van der Wal, W. M., Wanders, R. J., and Wijburg, F. A. (2013) Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans. J. Inherited Metabolic Disease 36, 247–255

9. Fuller, M., Meikle, P. J., and Hopwood, J. J. (2004) Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. Glycobiology 14, 443–450

10. Holley, R. J., Deligny, A., Wei, W., Watson, H. A., Ninouneou, M. R., Dagdý, A., Leary, J. A., Bigger, B. W., Kijellén, L., and Merry, C. L. (2011) Mucopolysaccharidosis type I unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking α-1-iduronidase. J. Biol. Chem. 286, 37515–37524

11. Murphy, J. W., Cho, Y., Schapatzidis, A., Fan, C., Hodsdon, M. E., and Lolis, E. (2007) Structural and functional basis of CXCL12 (stromal cell-derived factor-1α) binding to heparin. J. Biol. Chem. 282, 10018–10027

12. Netelenbos, T., Zuijderduijn, S., Van Den Born, J., Kessler, F. L., Zweegman, S., Huigens, P. C., and Dräger, A. M. (2002) Proteoglycans guide SDF-1-induced migration of hematopoietic progenitor cells. J. Leukocyte Biol. 72, 353–362

13. Proudfoot, A. E., Handel, T. M., Johnson, Z., Lau, E. K., LiWang, P., Clark-Lewis, I., Borlat, F., Wells, T. N., and Kosco-Vilbois, M. H. (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. U.S.A. 100, 1885–1890

14. Kuschert, G. S. V., Coulin, F., Power, C. A., Proudfoot, A. E. I., Hubbard, R. E., Hoogewerf, A. J., and Wells, T. N. C. (1999) Glycosaminoglycans Interact Selectively with Chemokines and Modulate Receptor Binding and Cellular Responses. Biochemistry 38, 12959–12968

15. Merry, C. L., Lyon, M., Deakin, J. A., Hopwood, J. J., and Gallagher, J. T. (1999) Highly sensitive sequencing of the sulfated domains of heparan sulfate. J. Biol. Chem. 274, 18455–18462

16. Wright, D. E., Bowman, E. P., Wagers, A. J., Butcher, E. C., and Weissman, J. I. (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. J. Exp. Med. 201, 1331–1339

17. Khan, S. A., Nelson, M. S., Pan, C., Gaffney, P. M., and Gupta, P. (2008) Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I. J. Inherit. Metab. Dis. 31, 1331–1339

18. Baxter, M. A., Wynn, R. F., Schyma, L., Holmes, D. K., Wraith, J. E., Fairbairn, L. J., and Bellantuono, I. (2005) Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development. J. Inherit. Metab. Dis. 28, 1045–1053

19. Pan, C., Caruelle, D., Frescaline, G., Delbée, J., Petit-Coacut, L., Huet, E., Charnaux, N., Uzan, G., Papy-Garcia, D., and Courty, J. (2009) Glycosaminoglycan mimetics-induced mobilization of hematopoietic progenitors and stem cells into mouse peripheral blood: structure/function insights. Exp. Hematol. 37, 1072–1081

20. Sweeney, E. A., and Papayannopoulou, T. (2001) Increase in circulating progenitor cells. J. Clin. Invest. 108, 1331–1339

21. Deakin, J. A., and Lyon, M. (2008) A simplified and sensitive fluorescent method for discaricahde analysis of both heparan sulfate and chondroitin/dermatan sulfates from biological samples. Glycobiology 18, 483–491

22. Lensen, J. F., Rops, A. L., Wijnhoven, T. J., Hafmans, T., Feitz, W. F., Veltman, J. A., Berden, J. H., and van Kuppevelt, T. H. (2006) 3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody H9251. J. Biol. Chem. 281, 4654–4662

23. van Kuppevelt, T. H., Dennissen, M. A., and Venrooij, W. J., Hoet, R. M. A., and Veerkamp, J. H. (1998) Generation and Application of Type-specific Anti-Heparan Sulfate Antibodies Using Phage Display Technology. Fur...
ther Evidence for Heparan Sulfate Heterogeneity in the Kidney. J. Biol. Chem. 273, 12960–12966
39. Saif, M. A., Bigger, B. W., Brookes, K. E., Mercer, J., Tylee, K. L., Church, H. J., Bonney, D. K., Jones, S., Wraith, J. E., and Wynn, R. F. (2012) Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler’s syndrome after pharmacological enzyme replacement therapy. Haematologica 97, 1320–1328
40. David, G., Bai, X. M., Van der Schueren, B., Cassiman, J. J., and Van den Bergh, H. (1992) Developmental changes in heparan sulfate expression: in situ detection with mAbs. J. Cell Biol. 119, 961–975
41. Wilson, S., Hashamiyan, S., Clarke, L., Saftig, P., Mort, J., Dejica, V. M., and Brömme, D. (2009) Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am. J. Pathol. 175, 2053–2062
42. Lawrence, R., Brown, J. R., Al-Mafraji, K., Lamanna, W. C., Beitel, J. R., Boons, G. J., Esko, J. D., and Crawford, B. E. (2012) Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat. Chem. Biol. 8, 197–204
43. Rueda, P., Richart, A., Récalde, A., Gasse, P., Vilar, J., Guérin, C., Lortat-Jacob, H., Vieira, P., Baleux, F., Chretien, F., Arenzana-Seisdedos, F., and Silvestre, J. S. (2012) Homeostatic and tissue reparation defaults in mice carrying selective genetic invalidation of CXCL12/proteoglycan interactions. Circulation 126, 1882–1895
44. Langford-Smith, K., Arasaradnam, M., Wraith, J. E., Wynn, R., and Bigger, B. W. (2010) Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Molecular Genetics Metabolism 99, 269–274
45. Langford-Smith, K. J., Mercer, J., Petty, J., Tylee, K., Church, H., Roberts, J., Moss, G., Jones, S., Wynn, R., Wraith, J. E., and Bigger, B. W. (2011) Heparin cofactor II-thrombin complex and dermatan sulphate/chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases. J. Inherited Metab. Dis. 34, 499–508
46. Langford-Smith, K. J., Sandiford, Z., Langford-Smith, A., Wilkinson, F. L., Jones, S. A., Wraith, J. E., Wynn, R. F., and Bigger, B. W. (2013) Signal One and Two Blockade Are Both Critical for Non-Myeloablative Murine HSCT across a Major Histocompatibility Complex Barrier. PloS one 8, e77632
